Find a Doctor

Physician Photo

Paul Edward Goss, MB BCh

Director, Breast Center Research

Co-Director, Breast Cancer Disease Program, DF/HCC

  • Phone: 617-726-6500
Departments
Hematology/Oncology
Department of Medicine

Specialties

  • Cancer Center
  • Breast Cancer
Clinical Interests
Aromatase inhibitors as hormonal therapy for breast cancer
Breast cancer
Locations
Boston: Massachusetts General Hospital
Medical Education
PhD, University of London
MBBCH, University of Witwatersrand
Residency, Charing Cross Hospital
Residency, St. Helier Hospital
Fellowship, Royal Marsden Hospital
Gender
Male
Foreign Languages
Afrikaans
Patient Age Group
Adult
Accepting New Patients
Yes

Publications

Dr. Goss has published over 200 original articles on his research of breast cancer. Below are highlighted publications of NCIC CTG MA.17.

Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women. J Clin Oncol. 2005;23(28):6931-6940.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. JClin Oncol. 2007;25(15):2006-11.

Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. J Clin Oncol. 2008;26(12):1948-55.7.

Breakthroughs from ASCO

Cancer Center investigators and physician-scientists share promising research and treatment developments in breast cancer, melanoma and more.

Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.

Gene-expression-based biomarker predicts long-term risk of breast cancer recurrence

A comparison of three methods of predicting recurrence risk in women treated for estrogen-receptor-positive breast cancer finds that only the breast cancer index – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of estrogen-blocking treatment.

Hematology/Oncology
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-726-6500
Phone 2: 617-724-3118
Fax: 617-724-1079

Hematology/Oncology
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-726-6500
Phone 2: 617-724-3118
Fax: 617-724-1079

Request a new patient appointment

Call the Massachusetts General Hospital physician referral service at 800-711-4644.

Insurance plans - what you need to know

Mass General accepts most health insurance plans. Find out what you need to know before coming to Mass General.

Directions to Mass General

Driving to Mass General? Get driving directions or locate a parking lot on the hospital's main campus.